BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 21563157)

  • 1. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
    Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
    Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
    Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
    Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
    Shelley MD; Wilt TJ; Court J; Coles B; Kynaston H; Mason MD
    BJU Int; 2004 Mar; 93(4):485-90. PubMed ID: 15008714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
    Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
    Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
    Shelley MD; Kynaston H; Court J; Wilt TJ; Coles B; Burgon K; Mason MD
    BJU Int; 2001 Aug; 88(3):209-16. PubMed ID: 11488731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.
    van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R;
    J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Chen S; Zhang N; Shao J; Wang X
    Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.